James Loerop insider trades

Open-market stock purchases and sales by James Loerop, Chief Business Officer at Aclaris Therapeutics, Inc, from SEC Form 4 filings since Jul 8, 2019.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -44%.

Recent trades

DateStockTradeValue
Feb 3, 2026ACRS Aclaris Therapeutics, IncSold (not open market)$20.6K
Feb 3, 2026ACRS Aclaris Therapeutics, IncBought (not open market)—
Feb 2, 2026ACRS Aclaris Therapeutics, IncBought (not open market)—
Feb 2, 2026ACRS Aclaris Therapeutics, IncBought (not open market)—
Feb 1, 2026ACRS Aclaris Therapeutics, IncSold (not open market)$37.5K
Feb 1, 2026ACRS Aclaris Therapeutics, IncBought (not open market)—
Feb 1, 2026ACRS Aclaris Therapeutics, IncBought (not open market)—
Feb 1, 2026ACRS Aclaris Therapeutics, IncBought (not open market)—
Jan 2, 2026ACRS Aclaris Therapeutics, IncSold (not open market)$17.8K
Jan 2, 2026ACRS Aclaris Therapeutics, IncBought (not open market)—
Dec 31, 2025ACRS Aclaris Therapeutics, IncSold (not open market)$102K
Dec 31, 2025ACRS Aclaris Therapeutics, IncBought (not open market)—

Companies traded

  • ACRS Aclaris Therapeutics, Inc: 1 buy, 1 sale, last Feb 3, 2026
  • ANIK Anika Therapeutics, Inc: 1 sale, last Jul 8, 2021

Get free alerts when James Loerop files a new trade →